Ruseva Aleksandrina, Dabbous Firas, Ding Nina, Fabricatore Anthony, Huse Samuel, Michalak Wojciech, Nordstrom Beth, Ó Hartaigh Bríain, Zhao Zhenxiang, Umashanker Devika
Novo Nordisk Inc, Plainsboro, NJ, USA.
Evidera Inc, Bethesda, MD, USA.
Postgrad Med. 2025 Apr-May;137(3-4):251-260. doi: 10.1080/00325481.2025.2482274. Epub 2025 Mar 27.
To evaluate the effectiveness of semaglutide 2.4 mg for weight reduction and improvement in cardiometabolic biomarkers at 52 and 68 weeks in a real-world setting in the United States.
This noninterventional, retrospective cohort study used the Komodo Health database and included adults with obesity or overweight with ≥1 weight-related condition who initiated treatment with semaglutide 2.4 mg between June 2021 and August 2022 and remained on treatment for 1 year. A paired t-test was used to assess changes in weight, body mass index (BMI), and cardiometabolic biomarkers (systolic blood pressure [SBP], diastolic blood pressure [DBP], glycated hemoglobin [HbA1c], HDL [high-density lipoprotein] cholesterol, LDL [low-density lipoprotein] cholesterol, and triglycerides) from baseline to 52-week and 68-week follow-up.
Among 4,424 eligible patients, 77% were women and the mean (SD) age was 46.7 (10.0) years and BMI was 36.6 (3.6) kg/m. Dyslipidemia and hypertension were the most common obesity-related comorbidities at baseline. The mean (%) change in weight from baseline was -15.5 kg (-14.5%; < 0.001; = 594) at 52 weeks and -15.9 kg (-14.8%; < 0.001; = 391) at 68 weeks. The mean change in BMI from baseline was - 4.8 kg/m ( = 1124) at 52 weeks and - 4.9 kg/m ( = 700) at 68 weeks. At 52weeks, statistically significant improvements in mean values were observed for SBP (-6.3 mmHg), DBP (-3.1 mmHg), HbA1c (-0.4%), LDL cholesterol (-8.1 mg/dL), and triglycerides (-38.4 mg/dL) (all < 0.001). Mean change at 52 weeks for HDL cholesterol was 1.0 mg/dL; = 0.109. Results at 68 weeks were similar.
In this retrospective cohort study, the real-world effectiveness of semaglutide 2.4 mg was demonstrated by reductions in weight and BMI along with improvements in BP, HbA1c, and lipid panel among patients with obesity or overweight.
评估司美格鲁肽2.4毫克在美国真实世界环境中，在52周和68周时减轻体重及改善心脏代谢生物标志物的有效性。
这项非干预性回顾性队列研究使用了科莫多健康数据库，纳入了患有肥胖症或超重且伴有≥1种与体重相关疾病的成年人，这些人在2021年6月至2022年8月期间开始使用2.4毫克司美格鲁肽治疗，并持续治疗1年。采用配对t检验评估从基线到52周和68周随访时体重、体重指数（BMI）和心脏代谢生物标志物（收缩压[SBP]、舒张压[DBP]、糖化血红蛋白[HbA1c]、高密度脂蛋白[HDL]胆固醇、低密度脂蛋白[LDL]胆固醇和甘油三酯）的变化。
在4424名符合条件的患者中，77%为女性，平均（标准差）年龄为46.7（10.0）岁，BMI为36.6（3.6）kg/m²。血脂异常和高血压是基线时最常见的与肥胖相关的合并症。52周时，体重较基线的平均（%）变化为-15.5千克（-14.5%；P<0.001；n=594），68周时为-15.9千克（-14.8%；P<0.001；n=391）。52周时，BMI较基线的平均变化为-4.8kg/m²（n=1124），68周时为-4.9kg/m²（n=700）。在52周时，观察到收缩压（-6.3mmHg）、舒张压（-3.1mmHg）、糖化血红蛋白（-0.4%）、低密度脂蛋白胆固醇（-8.1mg/dL）和甘油三酯（-38.4mg/dL）的平均值有统计学意义的改善（均P<0.001）。52周时高密度脂蛋白胆固醇的平均变化为1.0mg/dL；P=0.109。68周时的结果相似。
在这项回顾性队列研究中，2.4毫克司美格鲁肽在肥胖或超重患者中减轻体重和BMI，同时改善血压、糖化血红蛋白和血脂谱，证明了其在真实世界中的有效性。
